Biologics in bowel cancer
نویسندگان
چکیده
منابع مشابه
Immunogenicity of biologics in inflammatory bowel disease
Crohn's disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of patients lose response to biologics, partly due to the formation of anti-drug antibodies (ADAbs). Concomitant immunosuppressive agents reduce the development of ADAbs. This review article aims to assess the immunogenicity...
متن کاملImmunomodulators and Biologics for Inflammatory Bowel Disease
Azathioprine, 6-MP and Methotrexate were developed for cancer chemotherapy, but when used in small doses, they can be helpful for treating chronic inflammatory diseases such as IBD and some forms of arthritis. These are medications that reduce (suppress) the activity of the immune system by suppressing the bone marrow where immune cells are formed. These medications are called immunosuppressive...
متن کاملUse of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer
Patients with inflammatory bowel disease have an additional risk of developing cancer compared with the general population. This is due to local chronic inflammation that leads to the development of gastrointestinal cancers and the use of thiopurines, associated with a higher risk of lymphoproliferative disorders, skin cancers, or uterine cervical cancers. Similar to the general population, a p...
متن کاملBiologics, cardiovascular effects and cancer
Rheumatoid arthritis (RA) is associated with increased cardiovascular risk. Treatment with tumor necrosis factor (TNF)-inhibitors leads to about a 50% reduction in the first cardiovascular event. TNF-inhibitors could transiently improve flow-mediated vasodilation and improve carotid intima-media thickness (ccIMT) during the treatment of RA. Treatment with TNF-inhibitors is associated with an in...
متن کاملInflammatory Bowel Disease: Updates on Molecular Targets for Biologics
Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. T...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Gastrointestinal Oncology
سال: 2017
ISSN: 2078-6891,2219-679X
DOI: 10.21037/jgo.2017.05.03